$3.33
6.91% yesterday
Nasdaq, Nov 25, 09:50 pm CET
ISIN
US90138Q1085
Symbol
ME
Sector
Industry

23andMe Holding Co - Ordinary Shares - Class A Stock price

$3.29
-1.38 29.55% 1M
-6.97 67.94% 6M
-14.98 81.99% YTD
-14.89 81.90% 1Y
-180.61 98.21% 3Y
-192.71 98.32% 5Y
-192.71 98.32% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.18 5.79%
ISIN
US90138Q1085
Symbol
ME
Sector
Industry

Key metrics

Market capitalization $610.15m
Enterprise Value $553.74m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.87
P/S ratio (TTM) P/S ratio 3.16
P/B ratio (TTM) P/B ratio 0.83
Revenue growth (TTM) Revenue growth -28.47%
Revenue (TTM) Revenue $193.26m
EBIT (operating result TTM) EBIT $-270.71m
Free Cash Flow (TTM) Free Cash Flow $-123.03m
Cash position $128.10m
EPS (TTM) EPS $-25.27
P/E forward negative
P/S forward 0.89
EV/Sales forward 0.31
Short interest 6.15%
Show more

Is 23andMe Holding Co - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

23andMe Holding Co - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a 23andMe Holding Co - Ordinary Shares - Class A forecast:

1x Buy
50%
1x Hold
50%

Analyst Opinions

2 Analysts have issued a 23andMe Holding Co - Ordinary Shares - Class A forecast:

Buy
50%
Hold
50%

Financial data from 23andMe Holding Co - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
193 193
28% 28%
100%
- Direct Costs 129 129
29% 29%
67%
64 64
28% 28%
33%
- Selling and Administrative Expenses 142 142
18% 18%
73%
- Research and Development Expense 167 167
27% 27%
87%
-245 -245
22% 22%
-127%
- Depreciation and Amortization 26 26
24% 24%
13%
EBIT (Operating Income) EBIT -271 -271
22% 22%
-140%
Net Profit -615 -615
83% 83%
-318%

In millions USD.

Don't miss a Thing! We will send you all news about 23andMe Holding Co - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

23andMe Holding Co - Ordinary Shares - Class A Stock News

Neutral
GlobeNewsWire
6 days ago
SUNNYVALE, Calif. and SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and preventive health company, and Mirador Therapeutics, a next-generation precision medicine company focused on developing first-in-class or best-in-class therapeutics for immunology and inflammation (I&I)-related diseases, today announced a strategic research collabora...
Neutral
Seeking Alpha
14 days ago
23andMe Holding Co. (NASDAQ:ME ) Q2 2025 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Katie Watson - Vice President, Communications Anne Wojcicki - Chief Executive Officer & Co-Founder Joe Selsavage - Chief Financial Officer & Chief Accounting Officer Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the 23andMe Fiscal Year 2...
Negative
TechCrunch
14 days ago
23andMe announced on Monday it would cut 40% of its workforce, representing more than 200 employees, as part of a restructuring at the company. The genetic testing company is also discontinuing its therapeutics business and winding down its clinical trials; it expects these changes to save $35 million annually.
More 23andMe Holding Co - Ordinary Shares - Class A News

Company Profile

23andMe Holding Co. is consumer genetics and research company, which engages to help people access, understand, and benefit from the human genome. It provides direct access to genetic information with multiple Food and Drug Administration authorizations for genetic health risk reports. The firm’s research platform has generated publications on the genetic underpinnings of a range of diseases, conditions, and traits. The platform also powers the 23andMe therapeutics group, pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. The company was founded by Anne E. Wojcickiin 2006 and is headquartered in Sunnyvale, CA.

Head office United States
CEO Anne Wojcicki
Employees 582
Founded 2006
Website www.23andme.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today